Posted by Michael Wonder on 04 Jun 2018
Palatin Technologies announces FDA acceptance for review of bremelanotide NDA
4 June 2018 - PDUFA target action date 23 March 2019.
Palatin Technologies announced today that the U.S. FDA has accepted the bremelanotide new drug application for filing.
The application was filed on 23 March 2018 by AMAG Pharmaceuticals, the Company's exclusive North American licensee. Bremelanotide, an investigational melanocortin agonist, is being developed for the treatment of hypoactive sexual desire disorder in pre-menopausal women.
